Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | CCKAR | P32238 | 8/20 | 0.34 |
| ▸ | CCKBR | P32239 | 8/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13034771 | 1.00 | GLP1R (0.48) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL16408121 | 1.00 | GLP1R (0.48) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL12981346 | 0.99 | GLP1R (0.49) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL12122193 | 0.99 | GLP1R (0.46) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL16093428 | 0.98 | GLP1R (0.44) | GLP1RFOLH1CCKARCCKBRGLO1 | |
| SCHEMBL19957501 | 0.96 | GLP1R (0.42) | GLP1RCCKARCCKBRNOD1 | |
| SCHEMBL19069720 | 0.96 | GLP1R (0.43) | GLP1RFOLH1CCKARCCKBR | |
| SCHEMBL14819889 | 0.94 | GLP1R (0.46) | GLP1RCCKARCCKBR | |
| SCHEMBL14821762 | 0.94 | GLP1R (0.46) | GLP1RCCKARCCKBR | |
| SCHEMBL13034781 | 0.93 | GLP1R (0.43) | GLP1RFOLH1CCKARCCKBRGLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732137-B2 | Semi-recombinant preparation of GLP-1 analogues | NOVO NORDISK A/S (DK) | 2017-08-15 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292133-A1 | TRUNCATED GLP-1 DERIVATIES AND THEIR THERAPEUTICAL USE | GLP1R, GIPR, IAPP | GLP1R 1/4885FOLH1 1672/4885CCKAR 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.